XOMA (NASDAQ:XOMA)

View All ReportsStreetInsider.com Reports on XOMA

Feb 9, 2010 08:19 AM XOMA (XOMA) Begins Enrollment for XOMA 052 Phase 2b

Feb 2, 2010 08:52 AM XOMA Announces $21 Million Underwritten Offering of Common Shares and Warrants

Jan 19, 2010 08:20 AM XOMA (XOMA) Updates on FY10 Objectives; Issues FY09 Review

Dec 22, 2009 09:35 AM XOMA (XOMA) Gets 'Going Concern' Removed from Financial Statements

Nov 18, 2009 10:55 AM Notable Analyst Rating Changes 11/18: SII, ZMH, FSLR, PHM Upgraded; TGT, ADSK, VIP, JEC, PARD Downgraded

View All Press ReleasesCompany Press Releases on XOMA

Feb 9, 2010 07:00AM XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients

Feb 3, 2010 04:02PM XOMA Announces Presentation at BIO CEO and Investor Conference on February 9

Feb 3, 2010 09:00AM Liberty Analytics Co. Initiates Independent Research Coverage on XOMA Ltd.

Feb 2, 2010 08:45AM XOMA Announces $21 Million Underwritten Offering of Common Shares and Warrants

Jan 19, 2010 07:30AM XOMA Reviews Priorities for 2010 and 2009 Accomplishments

StreetInsider Reports on XOMA by Category

• Analyst Ratings
• Mergers and Acquisitions
• Earnings
• Guidance
• Stock Buybacks
• Dividends
• Retail Sales
• Management Changes
• Insider Trades
• View More Categories

View All BlogsBlogs on XOMA

Dec 10, 2009 04:55 AM Graft-Versus-Host Disease: Failures and Future Opportunities

Nov 9, 2009 01:19 PM XOMA Ltd. Q3 2009 Earnings Call Transcript

Sep 9, 2009 04:29 PM Closing Update for Wednesday, Sept. 9

Aug 7, 2009 07:05 AM XOMA Ltd. Q2 2009 Earnings Call Transcript

Jun 5, 2009 02:50 PM Friday's BioPlay: Xoma Ltd.

View All FilingsSEC Filings on XOMA

Feb 3, 2010 02:12PM Form 8-K/A XOMA LTD /DE/ For: Feb 02

Feb 2, 2010 08:51AM Form 8-K XOMA LTD /DE/ For: Feb 02

Dec 29, 2009 04:17PM Form 8-K XOMA LTD /DE/ For: Dec 29

Dec 22, 2009 08:15AM Form 8-K XOMA LTD /DE/ For: Dec 22

View All Comments Comments on recent XOMA articles

Bruce Lee
on Jan 17, 2010
at 05:24 PM Asian Partnership, perhaps? 7th Annual BIO Asia Partnering Conference http://bioasia.bio.org/opencms/bioasia/2010 January 25-26, 2010 Tokyo, Japan Takeda Pharmaceutical, Japan's largest drugmaker, hurt by diabetes drug U.S. setback, expects a delay until March 2012 or later in U.S approval of its key diabetes drug SYR-322.
Article: XOMA (XOMA) Gets 'Going Concern' Removed from Financial Statements

Mark J.
on Jan 16, 2010
at 12:00 AM Never sell to Shorts on Friday Especially if their name is Francesco. Thc company is setting itself up for a big move and most likely an Asian partner. March 2010 should tell the tale, don't miss the boat. There are a lot of irons in this fire and short interest will soon be badly burned.
Article: XOMA (XOMA) Posts Q3 EPS of $0.01, Misses by 1c

Michael
on Dec 25, 2009
at 11:00 PM Upside Potential Royalties On CIMZIA will be substancially increasing, since bacterial cell expression (BCE) technology licensee UCB S.A. has received FDA approval to market CIMZIA(r) (certolizumab pegol), an anti-tumor necrosis factor product, for the treatment of moderate to severe rheumatoid arthritis (RA) in adults. XOMA will receive royalty payments on sales of CIMZIA for this indication and will continue to receive royalties on sales of CIMZIA for the treatment of moderate to severe Crohn's disease, for which it was approved in April 2008. XOMA used previous CIMZIA Royalties to fully repay its loan with Goldman Sachs Specialty Holdings, but those royalites were before the new indication. The company is a heavily short sold buyout candidate which has recently paid off heavy debt, using existing royalties. It would be foolish to think XOMA is not heading north in a big way, very soon. http://www.metacafe.com/watch/3925223/xoma_ltd_biocentury_newsmakers_in_the_biotech_industry/
Article: XOMA (XOMA) Gets 'Going Concern' Removed from Financial Statements

Jordan
on Dec 22, 2009
at 07:54 PM xoma Thanks for your comment. very informative
Article: XOMA (XOMA) Gets 'Going Concern' Removed from Financial Statements

Gates
on Dec 22, 2009
at 10:05 AM Xoma's Strengths I'm an Xoma shareholder that believes my stock deserves more investor support. I made a verifiable list of facts that suggest the stock is grossly undervalued. 1. TAE technology. Makes antibodies many times more powerful and removes residual toxicity. Pure cash to bottom line. Made Xoma a profitable bio this year. 2. Xoma052 best in class for Type II diabetes. Phase II trial expanded to 4 sites. 3. Xoma052 in Type I Diabetes P2 4. 052 for Cardio P2. 5. Xoma3ab for possible 300 to 500 million stockpiling contract. 6. Partnered multiple drugs with Novartis. HCD122 in phase II. Other undisclosed. 7. Partnered multiple undisclosed drugs with Merck. 8. Partnered multiple undisclosed drugs with Takeda. 9. Interest in undisclosed drugs from more than 50 companies with BCE licenses. Cimzia currently paying royalties. 10. Xoma is debt free except for 13 million held against interest in HCD122. 11. Xoma should have between 50 and 60 million in the bank since they had 27 at end of 3rd Q. and got 33 million from licenses in Oct. 12. Stock is trading at about 1.1 times sales. Peer average is 16. 13. Gov. contract generating more than 20 million next year. 14. Gov. contracted Xoma to work on Swine Flu, Bird Flu, and SARS. 15. Xoma has backlog of contracts with Novartis, Merck and Takeda valued in excess of 500 million. 16. Xoma just announced a multiple antibody delivery technology that will be generating revenues next year. 17. Xoma has been hiring VP's and numerous scientists lately. 18. Analysts have buys on stock with near term price of 2.40 19. 09 Revenue will be about 120 million which is the current Market Cap. 20. Hudson Bay bought 12 million shares recently at $1.15 . 21. Azimuth bought 40 million shares at between 1.25 and .75 22. Insiders bought shares higher than the current price also. 23. Opebacan host vs. graft phase II ended last month. Possible radiation sickness use from this data and the burn phase II trial. 24. Xoma052 RA phase II trial ended in Nov. Gates
Article: XOMA Reports Removal of "Going Concern" Qualification

Comments on XOMA

No comments are currently available.

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?